ArticleJournal of virology2020
Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 178 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
178 citing papers in PubMed, 1 synthesis or guideline pooled it, 233 citations in OpenAlex.
- Pooled it
- The Water-Soluble [60]Fullerene Derivatives as Binders of SARS-CoV‑2 Proteins.ACS medicinal chemistry letters · 2026Article
- Search for Specific Inhibitors Targeting Type IA Topoisomerases.Journal of molecular biology · 2026Review
- First real-world evidence from the Emilia-Romagna region suggests tamoxifen protects breast cancer patients from COVID-19.Scientific reports · 2025Article
- Cardiovascular Impact in Patients With COVID-19 in Bangladesh: A Cross-Sectional Study.Cureus · 2025Article
- The mammalian SKI complex is a broad-spectrum antiviral drug target that upregulates cellular cholesterol to inhibit viral replication.Journal of virology · 2025Article
- Innate immune and endoplasmic reticulum unfolded protein response pathways protectJournal of biosciences · 2025Article
- Cell-based high-content approach for SARS-CoV-2 neutralization identifies unique monoclonal antibodies and PI3K pathway inhibitors.Frontiers in cell and developmental biology · 2025Article
- Promising therapeutics of enterovirus 71 infection: sunshine behind cloud.Frontiers in pharmacology · 2025Review
- PBPK-led assessment of antimalarial drugs as candidates for Covid-19: Simulating concentrations at the site of action to inform repurposing strategies.Clinical and translational science · 2024Article
- Colloidal Aggregation Confounds Cell-Based Covid-19 Antiviral Screens.Journal of medicinal chemistry · 2024Article
- The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis and clinical assessment: an updated meta-analysis of randomized trials.Journal of thoracic disease · 2024Article
- Aripiprazole as protector against COVID-19 mortality.Scientific reports · 2024Article
- Molecular docking as a tool for the discovery of novel insight about the role of acid sphingomyelinase inhibitors in SARS- CoV-2 infectivity.BMC public health · 2024Review
- CNP blocks mitochondrial depolarization and inhibits SARS-CoV-2 replicationbioRxiv : the preprint server for biology · 2023Article
- CNP blocks mitochondrial depolarization and inhibits SARS-CoV-2 replication in vitro and in vivo.PLoS pathogens · 2023Article
- Diet-induced obesity and diabetes enhance mortality and reduce vaccine efficacy for SARS-CoV-2.Journal of virology · 2023Article
- Article
- Colloidal aggregation confounds cell-based Covid-19 antiviral screens.bioRxiv : the preprint server for biology · 2023Article
- Risk Factors for the Prescription of Ineffective Antiviral Candidates for COVID-19 During the Early Pandemic Period in Korea.Journal of Korean medical science · 2023Article
118 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China at the end of 2019 and has rapidly caused a pandemic, with over 20 million recorded COVID-19 cases in August 2020 (https://covid19.who.int/). There are no FDA-approved antivirals or vaccines for any coronavirus, including SARS-CoV-2. Current treatments for COVID-19 are limited to supportive therapies and off-label use of FDA-approved drugs. Rapid development and human testing of potential antivirals is urgently needed. Numerous drugs are already approved for human use, and subsequently, there is a good understanding of their safety profiles and potential side effects, making them easier to fast-track to clinical studies in COVID-19 patients. Here, we present data on the antiviral activity of 20 FDA-approved drugs against SARS-CoV-2 that also inhibit SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). We found that 17 of these inhibit SARS-CoV-2 at non-cytotoxic concentrations. We directly followed up seven of these to demonstrate that all are capable of inhibiting infectious SARS-CoV-2 production. Moreover, we evaluated two of these, chloroquine and chlorpromazine,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.